Market revenue in 2023 | USD 324.5 million |
Market revenue in 2030 | USD 610.9 million |
Growth rate | 9.5% (CAGR from 2023 to 2030) |
Largest segment | Small molecule |
Fastest growing segment | Small Molecule |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Small Molecule |
Key market players worldwide | Boehringer Ingelheim, Baxter International Inc, Vetter Pharma-Fertigung, Recipharm, Fresenius Kabi, Ajinomoto, PCI Pharma Services, IDT Biologika, Alcami, Fareva, Eurofins Scientific SE, Siegfried Holding AG |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to sterile injectables cdmo market will help companies and investors design strategic landscapes.
Small molecule was the largest segment with a revenue share of 100% in 2023. Horizon Databook has segmented the Latin America sterile injectables cdmo market based on small molecule covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of continent-level data and insights on the Latin America sterile injectables cdmo market , including forecasts for subscribers. This continent databook contains high-level insights into Latin America sterile injectables cdmo market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account